UDO J. WILE, M.D., F.A.C.P.; JOSEPH A. BENSON, M.D.
This content is PDF only. Please click on the PDF icon to access.
Phenobarbital, chemically a white colorless substance, phenylethylbarbituric acid or phenylethylmalonylurea was first placed in the hands of clinicians in 1911 under the proprietary name of Luminal. Introduced as a sedative and hypnotic, its greatest success was in the treatment of epilepsy; and, at the present time, it is probably the most frequently prescribed sedative in modern medical practice.
A few months after its introduction, Loewe1 (1912) reported the first case of cutaneous reaction due to the ingestion of phenobarbital. He published his observations of three cases, each patient exhibiting a generalized macular eruption, without systemic reaction, the rash fading upon
WILE UJ, BENSON JA. EXFOLIATIVE DERMATITIS DUE TO PHENOBARBITAL WITH FATAL OUTCOME; REPORT OF TWO CASES1. Ann Intern Med. ;13:1243–1249. doi: 10.7326/0003-4819-13-7-1243
Download citation file:
Published: Ann Intern Med. 1940;13(7):1243-1249.
Education and Training.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use